A patient with the MZ alpha-1 antitrypsin (AAT) phenotype is at increased risk for chronic liver disease.
Forms of liver disease that may become chronic and progress to cirrhosis in patients with the MZ phenotype:
(1) nonalcoholic steatohepatitis (NASH)
(2) alcoholic hepatitis
(3) autoimmune hepatitis
(4) chronic active viral hepatitis
(5) methotrexate-induced liver disease
(6) cryptogenic liver disease
Complications of the chronic liver disease:
(1) hepatic failure
(2) hepatocellular carcinoma
(1) A person who develops unexplained chronic liver disease should be phenotyped for alpha-1 antitrypsin.
(2) A patient with the MZ phenotype should not be exposed to potentially hepatotoxic drugs or chemicals.
(3) A patient with the MZ phenotype who develops nonalcoholic steatohepatitis (NASH) should aggressively try to reverse the metabolic factors.
To read more or access our algorithms and calculators, please log in or register.
Specialty: Endocrinology, Clinical Laboratory, Gastroenterology